1
|
Rausch M, Dyson PJ, Nowak‐Sliwinska P. Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies. ADVANCED THERAPEUTICS 2019. [DOI: 10.1002/adtp.201900042] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Magdalena Rausch
- Molecular Pharmacology GroupSchool of Pharmaceutical Sciences, Faculty of SciencesUniversity of Lausanne and University of Geneva Rue Michel‐Servet 1, 1211 Geneva 4 Switzerland
| | - Paul J. Dyson
- Institute of Chemical Sciences and EngineeringEcole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne Switzerland
| | - Patrycja Nowak‐Sliwinska
- Molecular Pharmacology GroupSchool of Pharmaceutical Sciences, Faculty of SciencesUniversity of Lausanne and University of Geneva Rue Michel‐Servet 1, 1211 Geneva 4 Switzerland
- Translational Research Centre in Oncohaematology Geneva, Switzerland, 1211 Geneva 4 Switzerland
| |
Collapse
|
2
|
Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W. Metal Drugs and the Anticancer Immune Response. Chem Rev 2018; 119:1519-1624. [DOI: 10.1021/acs.chemrev.8b00396] [Citation(s) in RCA: 174] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Bernhard Englinger
- Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
| | - Christine Pirker
- Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
| | - Petra Heffeter
- Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
- Research Cluster “Translational Cancer Therapy Research”, University of Vienna and Medical University of Vienna, Vienna, Austria
| | - Alessio Terenzi
- Research Cluster “Translational Cancer Therapy Research”, University of Vienna and Medical University of Vienna, Vienna, Austria
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria
| | - Christian R. Kowol
- Research Cluster “Translational Cancer Therapy Research”, University of Vienna and Medical University of Vienna, Vienna, Austria
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria
| | - Bernhard K. Keppler
- Research Cluster “Translational Cancer Therapy Research”, University of Vienna and Medical University of Vienna, Vienna, Austria
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, A-1090 Vienna, Austria
| | - Walter Berger
- Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria
- Research Cluster “Translational Cancer Therapy Research”, University of Vienna and Medical University of Vienna, Vienna, Austria
| |
Collapse
|
3
|
Mello-Andrade F, da Costa WL, Pires WC, Pereira FDC, Cardoso CG, Lino-Junior RDS, Irusta VRC, Carneiro CC, de Melo-Reis PR, Castro CH, Almeida MAP, Batista AA, Silveira-Lacerda EDP. Antitumor effectiveness and mechanism of action of Ru(II)/amino acid/diphosphine complexes in the peritoneal carcinomatosis progression. Tumour Biol 2017; 39:1010428317695933. [DOI: 10.1177/1010428317695933] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Francyelli Mello-Andrade
- Laboratório de Genética Molecular e Citogenética, Departamento de Genética, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, Brazil
| | - Wanderson Lucas da Costa
- Laboratório de Genética Molecular e Citogenética, Departamento de Genética, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, Brazil
| | - Wanessa Carvalho Pires
- Laboratório de Genética Molecular e Citogenética, Departamento de Genética, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, Brazil
| | - Flávia de Castro Pereira
- Laboratório de Genética Molecular e Citogenética, Departamento de Genética, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, Brazil
| | - Clever Gomes Cardoso
- Departamento de Morfologia, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, Brazil
| | - Ruy de Souza Lino-Junior
- Laboratório de Patologia Geral, Departamento de Microbiologia, Imunologia, Parasitologia e Patologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil
| | | | - Cristiene Costa Carneiro
- Laboratório de Radiobiologia de Microrganismos e Mutagênese, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, Brazil
| | - Paulo Roberto de Melo-Reis
- Laboratório de Estudos Experimentais em Biotecnologia, Departamento de Biomedicina, Pontifícia Universidade Católica de Goiás, Goiânia, Brazil
| | - Carlos Henrique Castro
- Laboratório de Fisiologia Autonômica e Cardíaca, Departamento de Fisiologia e Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, Brazil
| | | | | | - Elisângela de Paula Silveira-Lacerda
- Laboratório de Genética Molecular e Citogenética, Departamento de Genética, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Goiânia, Brazil
| |
Collapse
|
4
|
Magalhães LF, Mello-Andrade F, Pires WC, Silva HD, da Silva PFF, Macedo LM, Henrique de Castro C, Carneiro CC, Cardoso CG, de Melo Reis PR, Camargo de Oliveira L, Caetano RR, Batista AA, Silveira-Lacerda EDP. cis-[RuCl(BzCN)(bipy)(dppe)]PF6 induces anti-angiogenesis and apoptosis by a mechanism of caspase-dependent involving DNA damage, PARP activation, and Tp53 induction in Ehrlich tumor cells. Chem Biol Interact 2017; 278:101-113. [PMID: 28935426 DOI: 10.1016/j.cbi.2017.09.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Accepted: 09/12/2017] [Indexed: 12/18/2022]
Abstract
Antimetastatic activities, low toxicity to normal cells and high selectivity for tumor cells make of the ruthenium complexes promising candidates in the search for develop new chemotherapeutic agents for the treatment of cancer. This study aimed to determine the cytotoxic, genotoxic and to elucidate the signaling pathway involved in the death cell process induced by cis-[RuCl(BzCN)(bipy)(dppb)]PF6(1) and cis-[RuCl(BzCN)(bipy)(dppe)]PF6(2) in Ehrlich ascites carcinoma (EAC) in vitro. Moreover, we report for the first time the anti-angiogenic potential on chick embryo chorioallantoic membrane (CAM) model. Peripheral blood mononuclear cells (PBMC) were isolated from healthy controls with an age range of 20-30 years and used to calculate the selectivity index (SI). The complex 2 (IC50 = 8.5 ± 0.4/SI = 6.3) showed high cytotoxic and selectivity index against EAC cells than complex 1 (IC50 = 14.9 ± 0.2/SI = 0.2) using the MTT assay. Complex 2 induced DNA damage on Ehrlich tumor cells at concentrations and time periods evalueted. In consequence, it was observed an increase of Tp53 gene expression, G0/G1-arrest cells, and increased levels of cleaved PARP protein. Beside that, the treatment of EAC with complex 2 led to an increase in Annexin V-positive cells and apoptosis induction by Caspase-7. Additionally, the complex 2 inhibited the angiogenesis caused by Ehrlich tumor cells in CAM model. This complex is active and selective for Ehrlich tumor cells, inducing DNA damage, cell cycle arrest and cell death by caspase-dependent apoptosis involving PARP activation (PARP1), and Tp53 induction.
Collapse
Affiliation(s)
- Lorena Félix Magalhães
- Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás - UFG, Goiânia, GO CEP 74001-970, Brazil
| | - Francyelli Mello-Andrade
- Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás - UFG, Goiânia, GO CEP 74001-970, Brazil
| | - Wanessa Carvalho Pires
- Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás - UFG, Goiânia, GO CEP 74001-970, Brazil
| | - Hugo Delleon Silva
- Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás - UFG, Goiânia, GO CEP 74001-970, Brazil
| | - Paula Francinete Faustino da Silva
- Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás - UFG, Goiânia, GO CEP 74001-970, Brazil
| | - Larissa Matuda Macedo
- Laboratory of Cardiovascular Phisiology, Institute of Biological Sciences, Federal University of Goiás - UFG, Goiânia, GO CEP 74001-970, Brazil
| | - Carlos Henrique de Castro
- Laboratory of Cardiovascular Phisiology, Institute of Biological Sciences, Federal University of Goiás - UFG, Goiânia, GO CEP 74001-970, Brazil
| | - Cristiene Costa Carneiro
- Mutagenesis and Microorganisms Radiobiology Laboratory, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO 74690-900, Brazil
| | - Clever Gomes Cardoso
- Department of Morphology, Institute of Biological Sciences, University Federal of Goiás, Goiânia, GO, Brazil
| | | | | | | | - Alzir A Batista
- Department of Chemistry, Federal University of São Carlos, SãoCarlos, SP CEP 13.565-905, Brazil
| | - Elisângela de Paula Silveira-Lacerda
- Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás - UFG, Goiânia, GO CEP 74001-970, Brazil.
| |
Collapse
|
5
|
Kaur J, Damle M, Mande H, Ghalsasi P, Kondedeshmukh R, Bandyopadhyay P, Chikate R. Ruthenium(II) complexes of aroylhydrazones: structural, electrochemical and electrostatic interactions with DNA. J COORD CHEM 2017. [DOI: 10.1080/00958972.2017.1307344] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Jatinder Kaur
- Department of Chemistry, Post-Graduate and Research Center, MES AbasahebGarware College, Pune, India
- Department of Chemistry, Fergusson College, Pune, India
| | - Madhura Damle
- Department of Chemistry, Post-Graduate and Research Center, MES AbasahebGarware College, Pune, India
| | - Hemant Mande
- Faculty of Science, Department of Chemistry, The Maharaja Sayajirao University of Baroda, Vadodara, India
| | - Prasanna Ghalsasi
- Faculty of Science, Department of Chemistry, The Maharaja Sayajirao University of Baroda, Vadodara, India
| | | | | | - Rajeev Chikate
- Department of Chemistry, Post-Graduate and Research Center, MES AbasahebGarware College, Pune, India
| |
Collapse
|
6
|
Cis-[RuCl(BzCN)(N-N)(P-P)]PF6 complexes: Synthesis and in vitro antitumor activity: (BzCN=benzonitrile; N-N=2,2'-bipyridine; 1,10-phenanthroline; P-P=1,4-bis(diphenylphosphino) butane, 1,2-bis(diphenylphosphino)ethane, or 1,1'-(diphenylphosphino)ferrocene). J Inorg Biochem 2015; 149:91-101. [PMID: 25873134 DOI: 10.1016/j.jinorgbio.2015.03.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Revised: 03/18/2015] [Accepted: 03/20/2015] [Indexed: 12/20/2022]
Abstract
The motivation to use ruthenium complexes in cancer treatment has led our research group to synthesize complexes with this metal and test them against several types of tumor cells, yielding promising results. In this paper the results of biological tests, assessed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, were carried out on the complexes cis-[RuCl(BzCN)(bipy)(dppe)]PF6 (1), cis-[RuCl(BzCN)(bipy)(dppb)]PF6 (2), cis-[RuCl(BzCN)(bipy)(dppf)]PF6 (3) and cis-[RuCl(BzCN)(phen)(dppb)]PF6 (4) which are described [BzCN = b enzonitrile; bipy = 2,2'-bipyridine; phen = 1,10-phenanthroline; dppe = 1,2-bis(diphenylphosphino) ethane; dppb = 1,4-bis-(diphenylphosphino)butane; dppf = 1,1'-bis(diphenylphosphino)ferrocene]. The present study is focused on the cytotoxic activity of complexes (1)-(4) against four tumor cell lines and on the apoptosis and changes in the cell cycle and gene expression observed in the sarcoma 180 (S180) tumor cell line treated with complex (1). The results demonstrated that this complex inhibits S180 cell growth, with an IC50 of 17.02 ± 8.21 μM, while exhibiting lower cytotoxicity (IC50 = 53.73 ± 5.71 μM) towards lymphocytes (normal cells). Flow cytometry revealed that the complex inhibits the growth of tumor cells by inducing apoptosis as evidenced by an increase in the proportion of cells positive for annexin V staining and G0/G1 phase cell-cycle arrest. Further investigation showed that complex (1) induces a drop in the mitochondrial membrane potential and provokes a decrease in Bcl-2 protein expression and increase in caspase 3 activation, while the increased activation of caspase 8 caused a decrease in the gene expression in caspases 3 and 9. Increases in Tp53 and Bax expressions were also observed.
Collapse
|
7
|
Swavey S, DeBeer M, Li K. Photoinduced Interactions of Supramolecular Ruthenium(II) Complexes with Plasmid DNA: Synthesis and Spectroscopic, Electrochemical, and DNA Photocleavage Studies. Inorg Chem 2015; 54:3139-47. [DOI: 10.1021/ic502340p] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Shawn Swavey
- SupraMolecular Applied Research
and Technology Center, Department of Chemistry, University of Dayton, 300 College Park, Dayton, Ohio 45469-2357, United States
| | - Madeleine DeBeer
- SupraMolecular Applied Research
and Technology Center, Department of Chemistry, University of Dayton, 300 College Park, Dayton, Ohio 45469-2357, United States
| | - Kaiyu Li
- SupraMolecular Applied Research
and Technology Center, Department of Chemistry, University of Dayton, 300 College Park, Dayton, Ohio 45469-2357, United States
| |
Collapse
|
8
|
Momcilovic M, Eichhorn T, Blazevski J, Schmidt H, Kaluđerović GN, Stosic-Grujicic S. In vitro effects of binuclear (η (6)-p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen. J Biol Inorg Chem 2015; 20:575-83. [PMID: 25827592 DOI: 10.1007/s00775-015-1242-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Accepted: 01/19/2015] [Indexed: 12/24/2022]
Abstract
T cell differentiation into distinct T helper (Th) subpopulations is crucial in governing acquired immune responses as well as some inflammatory and autoimmune disorders. This study investigated potential of the novel neutral binuclear ruthenium(II) complexes 1-8 with general formula [{RuCl2(η(6)-p-cym)}2μ-(N(∩)N)] (N(∩)N = bis(nicotinate)- and bis(iso-nicotinate)-polyethylene glycol esters; (3-py)COO(CH2CH2O) n CO(3-py) and (4-py)COO(CH2CH2O) n CO(4-py); n = 1-4), as well as [RuCl2(η(6)-p-cym)(nic)] (R1, nic = nicotinate) and [RuCl2(η(6)-p-cym)(inic)] (R2, inic = isonicotinate) as an immunomodulatory agents capable to direct Th cell differentiation. From all investigated complexes, [{RuCl2(η(6)-p-cym)}2μ-{(3-py)COO(CH2CH2O)4CO(3-py)}] (4) was selected for further study because it did not affect splenocyte viability (in concentration up to 50 μM), but significantly reduced secretion of representative Th1 cytokine, IFN-γ induced by T cell mitogen. Besides IFN-γ, 4 inhibited dose dependently expression and production of representative Th17 cytokine, IL-17, in these cells. Otherwise, the production of anti-inflammatory cytokines IL-4 and IL-10 was upregulated. Also, 4 significantly increased CD4(+)CD25(+)FoxP3(+) Treg cell frequency in the activated splenocytes. Moreover, ConA-induced expression of Th1 transcription factors, T-bet and STAT1, as well as of Th17-related protein STAT3 was attenuated upon exposure to 4, while the expression of Th2-related transcription factor GATA3 remained stable. In conclusion, ruthenium(II) complex 4 modulates immune system cell functions in vitro by inhibiting T cell differentiation towards pathogenic Th1/Th17 phenotype and inducing a regulatory phenotype characterized by IL-10 and IL-4 production, which may provide novel therapeutic opportunities for immune-inflammatory and/or autoimmune disorders.
Collapse
Affiliation(s)
- Miljana Momcilovic
- Department of Immunology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Bulevar Despota Stefana 142, 11060, Belgrade, Serbia,
| | | | | | | | | | | |
Collapse
|
9
|
Vilanova-Costa CAST, Porto HKP, Pereira LCG, Carvalho BP, Dos Santos WB, Silveira-Lacerda EDP. MDR1 and cytochrome P450 gene-expression profiles as markers of chemosensitivity in human chronic myelogenous leukemia cells treated with cisplatin and Ru(III) metallocomplexes. Biol Trace Elem Res 2015; 163:39-47. [PMID: 25253429 DOI: 10.1007/s12011-014-0133-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Accepted: 09/16/2014] [Indexed: 01/11/2023]
Abstract
Leukemia is a major type of cancer affecting a significant segment of the population, and especially children. In fact, leukemia is the most frequent childhood cancer, with 26 % of all cases, and 20 % mortality. The multidrug resistance phenotype (MDR) is considered one of the major causes of failure in cancer chemotherapy. The present study aimed to investigate the relationship between the expression of MDR1 and CYP450 genes in human chronic myelogenous leukemia cells (K-562) treated with cisplatin (cisPt) and two ruthenium-based coordinated complexes [cisCRu(III) and cisDRu(III)]. The tested compounds induced apoptosis in K-562 tumor cells as evidenced by caspase 3 activation. Results also revealed that the amplification of P-gp gene is greater in K-562 cells exposed to cisPt and cisCRu(III) than cisDRu(III). Taken together, all these results strongly demonstrate that MDR-1 overexpression in K-562 cells could be associated to a MDR phenotype, and moreover, it is also contributing to the platinum and structurally related compound, resistance in these cells.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B/biosynthesis
- Antineoplastic Combined Chemotherapy Protocols/pharmacology
- Apoptosis/drug effects
- Cisplatin/pharmacology
- Cytochrome P-450 Enzyme System/biosynthesis
- Drug Resistance, Multiple/drug effects
- Drug Resistance, Neoplasm/drug effects
- Gene Expression Regulation, Leukemic/drug effects
- Humans
- K562 Cells
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Ruthenium/pharmacology
Collapse
Affiliation(s)
- Cesar Augusto Sam Tiago Vilanova-Costa
- Laboratório de Genética Molecular e Citogenética, Instituto de Ciências Biológicas - ICB, Universidade Federal de Goiás - UFG, Campus Samambaia (Campus II), Cx. Postal: 131, Goiânia, GO, 74001-970, Brazil,
| | | | | | | | | | | |
Collapse
|
10
|
Martinčič A, Milačič R, Vidmar J, Turel I, Keppler BK, Ščančar J. New method for the speciation of ruthenium-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks. J Chromatogr A 2014; 1371:168-76. [DOI: 10.1016/j.chroma.2014.10.054] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2014] [Revised: 10/13/2014] [Accepted: 10/20/2014] [Indexed: 01/09/2023]
|
11
|
The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549). Biometals 2014; 27:459-69. [PMID: 24781824 DOI: 10.1007/s10534-014-9715-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2013] [Accepted: 02/06/2014] [Indexed: 10/25/2022]
Abstract
Lung cancer is one of the leading causes of death in the world, and non-small cell lung carcinoma accounts for approximately 75-85 % of all lung cancers. In the present work, we studied the antitumor activity of the compound cis-(dichloro)tetramineruthenium(III) chloride {cis-[RuCl2(NH3)4]Cl} against human lung carcinoma tumor cell line A549. The present study aimed to investigate the relationship between the expression of MDR1 and CYP450 genes in human lung carcinoma cell lines A549 treated with cisCarboPt, cisCRu(III) and cisDRu(III). The ruthenium-based coordinated complexes presented low cytotoxic and antiproliferative activities, with high IC50 values, 196 (±15.49), 472 (±20.29) and 175 (±1.41) for cisCarboPt, cisCRu(III) and cisDRu(III), respectively. The tested compounds induced apoptosis in A549 tumor cells as evidenced by caspase 3 activation, but only at high concentrations. Results also revealed that the amplification of P-gp gene is greater in A549 cells exposed to cisCarboPt and cisCRu(III) than cisDRu(III). Taken together all these results strongly demonstrate that MDR-1 over-expression in A549 cells could be associated to a MDR phenotype of these cells and moreover, it is also contributing to the platinum, and structurally-related compound, resistance in these cells. The identification and characterization of novel mechanisms of drug resistance will enable the development of a new generation of anti-cancer drugs that increase cancer sensitivity and/or represent more effective chemotherapeutic agents.
Collapse
|
12
|
The compound cis-(dichloro)tetrammineruthenium(III) chloride induces caspase-mediated apoptosis in K562 cells. Toxicol In Vitro 2010; 24:1562-8. [PMID: 20600797 DOI: 10.1016/j.tiv.2010.06.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2010] [Revised: 06/23/2010] [Accepted: 06/24/2010] [Indexed: 11/24/2022]
Abstract
Ruthenium(III) complexes are increasingly attracting the interest of researchers due to their promising pharmacological properties. In the present study, we investigated the ability of cis-(dichloro)tetrammineruthenium(III) chloride to produce lethal effects in human chronic myelogenous leukemia K562 cells. The MTT tetrazolium reduction test and the trypan blue exclusion assay revealed that the IC(50) for the compound after 48 h of incubation with K562 cells was approximately 10.74 and 73.45 microM, respectively. Interestingly, it was observed that this compound exhibits mild cytotoxicity towards MRC-5 human fibroblast cells (IC(50)>383 microM). Flow cytometric analysis revealed that cis-(dichloro)tetrammineruthenium(III) chloride was capable of change cell cycle distribution since the percentage of cells in the G1, S and G2 phases decreased. In addition, treatment with this compound induced apoptotic cell death in K562 cells, demonstrated by increased DNA content in the sub-G1-peak and a significant increase in caspase-3 activity. Assay using cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (MPT) showed that the preincubation of K562 cells with this inhibitor had not effect on cis-(dichloro)tetrammineruthenium(III) chloride induced caspase-3 activation. In summary, cis-(dichloro)tetrammineruthenium(III) chloride displayed a significant cytotoxic effect through cell cycle arrest and apoptotic induction in K562 cells, which suggests that cis-(dichloro)tetrammineruthenium(III) chloride might have therapeutic potential against leukemia.
Collapse
|